Halozyme and argenx have expanded their global collaboration to include two additional exclusive targets for ENHANZE technology, increasing argenx's access to the platform from six to eight targets.
Why it matters. Halozyme and argenx are expanding their partnership, which could lead to more convenient and accessible treatments for patients in various therapeutic areas.
will receive royalties on net sales of products using ENHANZE ® .
including facilitating more convenient administration and dosing regimens of injectable medications through subcutaneous delivery
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1....
Halozyme is headquartered in San Diego, CA
ENHANZE ® has touched more than one million patient lives
through ten commercialized products
Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids
it has expanded its global collaboration and license agreement with argenx
across over 100 global markets
Halozyme also develops, manufactures and commercializes drug-device combination products
"We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "The addition of two new exclusive targets further va…
SAN DIEGO , Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE ® with two additional exclusive…
